Peter Traber
Director/Board Member bei Baylor College of Medicine
Vermögen: 293 687 $ am 31.03.2024
Profil
Peter G.
Traber is currently the Chief Executive Officer at Baylor College of Medicine since 2003.
He previously held positions as the Chief Executive Officer at The University of Pennsylvania Health System, Chairman & Chief Executive Officer at Terrasep LLC, Chairman-Internal Medicine Department at the University of Pennsylvania Medical Center, Director at Noble International Ltd., Director at Tanox, Inc., and Independent Director at Caladrius Biosciences, Inc. From 2017 to 2018, he served as the President, Chief Executive & Medical Officer at Galectin Therapeutics, Inc. Currently, he is also the Chief Medical Officer at Selecta Biosciences, Inc. since 2020.
Prior to his current roles, he was the Chief Medical Officer & SVP-Clinical Development at GSK Plc from 2000 to 2003 and the Chief Medical Officer at Morphic Therapeutic, Inc. He also worked as a Partner at Alacrita Consulting Ltd.
from 2018 to 2020.
Dr. Traber received his undergraduate degree from the University of Michigan and his doctorate from The Wayne State University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,28% | 25.09.2023 | 451 826 ( 0,28% ) | 293 687 $ | 31.03.2024 |
Aktive Positionen von Peter Traber
| Unternehmen | Position | Beginn |
|---|---|---|
| Baylor College of Medicine | Director/Board Member | 01.01.2008 |
Ehemalige bekannte Positionen von Peter Traber
| Unternehmen | Position | Ende |
|---|---|---|
| CARTESIAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 13.11.2023 |
| Alacrita Consulting Ltd. | Corporate Officer/Principal | 01.08.2020 |
| GALECTIN THERAPEUTICS INC. | Chief Executive Officer | 06.07.2018 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Director/Board Member | 03.08.2007 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 01.01.2003 |
Ausbildung von Peter Traber
| University of Michigan | Undergraduate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GALECTIN THERAPEUTICS INC. | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Noble International Ltd.
 Noble International Ltd. Auto Parts: OEMProducer Manufacturing Noble International Ltd. manufactures and supplies automotive components, provides laser welding and cutting services. The company is headquartered in Troy, MI. | Producer Manufacturing |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
The University of Pennsylvania Health System
 The University of Pennsylvania Health System Miscellaneous Commercial ServicesCommercial Services The University of Pennsylvania Health System provides general patient care as well as medical education and research services. The company was founded in 1874 and is headquartered in Philadelphia, PA. | Commercial Services |
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
| Terrasep LLC | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Health Technology |
| Alacrita Consulting Ltd. |
